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Summary
Although studies on the immunopathogenesis of anti-neutrophil cytoplasm
antibody (ANCA) vasculitis have been directed at understanding the autoan-
tibody, there is growing evidence that points to the importance of ANCA
autoantigen genes and their regulation. Transcriptional analysis indicates that
ANCA autoantigen genes are active in mature neutrophils of ANCA vasculitis
patients compared to healthy controls. The unusual transcriptional state of
neutrophils from ANCA vasculitis patients appears to be a consequence of
failed or disrupted epigenetic silencing. Defective epigenetic silencing could
have global effects, by altering the transcriptional and phenotypic state of
neutrophils, or local effects by permitting transcription of autoantigen genes
from both strands resulting in anti-sense transcripts. Although the role of
anti-sense transcripts is currently unknown, there are two intriguing
possibilities. Anti-sense transcripts could function (as described for other
genes) in transcriptional silencing of autoantigen genes, which takes place in
normal neutrophil progenitors. In the setting of failed epigenetic silencing,
the fate of anti-sense transcripts may be pathological and serve as a template
for production of complementary autoantigens. The observation that ANCA
vasculitis patients have anti-sense transcripts and antibodies to complemen-
tary proteins is consistent with a role of anti-sense transcripts in complemen-
tary protein production. A better understanding of epigenetic silencing and
complementary proteins in ANCA vasculitis may unlock the underlying
pathology of this condition.
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Research on the immunopathogenesis in anti-neutrophil
cytoplasm antibody (ANCA) vasculitis has focused prima-
rily on the identity, origin and role of the autoantibody, with
little effort directed at understanding the role of the
autoantigen. The molecular mechanisms responsible for the
immunopathogenesis have not been unravelled completely,
but clinical and experimental evidence indicates that ANCA
cause vascular injury by activating neutrophils [1–5].
Despite data demonstrating that the presence of ANCA are
sufficient to cause disease, a number of factors can aggravate
the disease process, including environmental pressures, sug-
gesting that ANCA vasculitis escalates in patients who
harbour an additional defect(s). A fascinating possibility is
that the additional defect(s) contributes to the development
of the autoantibodies.
One candidate for an additional defect among
ANCA vasculitis patients is dysregulated gene expression,
leading to different transcriptional profiles of neutrophils
from ANCA patients compared to neutrophils from
healthy controls. Importantly, two major ANCA autoanti-
gens, granule proteins proteinase 3 (PR3) and myelo-
peroxidase (MPO), which are expressed predominantly
during the myeloblast and promyelocyte stages of
neutrophil development [6], are expressed aberrantly in
mature neutrophils of ANCA patients contrasted with
their normally silenced state in mature neutrophils of
healthy controls [7,8]. The aberrant expression of PR3 and
MPO genes in mature neutrophils from ANCA patients is
probably a consequence of defective epigenetic silencing
[9].
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Support for an epigenetic silencing defect among ANCA
vasculitis patients comes from chromatin immunoprecipita-
tion (ChIP) experiments which showed that the PR3 and
MPO genes in neutrophils of ANCA patients relative to
healthy controls are depleted of H3K27me3, a mark of tran-
scriptionally silent chromatin. The establishment and main-
tenance of this epigenetic silencing mark results from the
activities of a specific histone modifying complex (PRC2)
and its methyltransferase subunit (EZH2), and histone dem-
ethylases (JMJD3 and UTX) specific for H3K27me3. In
ANCA vasculitis patients the balance of histone methyl-
transferase and demethylase activity tilts away from silencing
because there is a failure to recruit PRC2 and EZH2 to the
PR3 and MPO genes, and there is increased expression of
JMJD3 and UTX. A further epigenetic silencing defect
involving DNA methylation has also been identified in
ANCA patients. A CpG island in the MPO gene remains
unmethylated in ANCA vasculitis patients while methylated
in healthy controls. These data suggest that epigenetic dys-
regulation is an important defect in ANCA vasculitis.
There are several potential consequences of epigenetic
dysregulation. The aberrant expression of PR3 and MPO
may be a surrogate marker for global epigenomic changes in
neutrophils of ANCA patients. The global epigenomic
changes manifest in distinct transcriptional profiles for neu-
trophils of ANCA patients [10], which may signify a neutro-
phil that responds more severely to autoantibodies. A second
consequence of the epigenetic defect could be specific to PR3
and MPO genes because the failure to silence these autoan-
tigen genes in mature neutrophils provides a template for
inappropriate production of these antigens. Inappropriate
expression of PR3 and MPO may alter the availability of
these antigens by targeting these proteins to granules that are
exocytosed more readily. Finally, the defect in epigenetic
gene silencing could provide an accessible or even permissive
chromatin template for anti-sense transcription.
Large RNA sequencing and transcriptome projects have
identified uncharacterized long non-coding RNAs surpass-
ing the number of known coding transcripts [11,12]. Some
of the more well-known long non-coding RNAs, such as
Xist, Air and Kcnq1ot1, function to regulate gene expres-
sion. A speculative model for transcriptional regulation of
PR3 and MPO would posit a role of anti-sense PR3 or
MPO transcripts in targeting silencing complexes, such as
PRC2, to PR3 or MPO loci, respectively. For instance,
during normal neutrophil development the gradual accu-
mulation of anti-sense PR3 transcripts in promyelocytes
would help to target PRC2 to the PR3 gene. Targeting PRC2
would establish H3K27me3 and transcriptional silencing
of the PR3 locus (both sense and anti-sense DNA
strands) observed in mature neutrophils. In ANCA
patients, according to this model, anti-sense transcripts that
accumulate in promyelocytes fail to establish and/or main-
tain H3K27me3 because either PRC2 is not recruited prop-
erly or the demethylase activity of JMJD3 and UTX erases
methylation of H3K27. In mature neutrophils of ANCA
patients the PR3 locus could then be transcribed from both
strands.
The presence of anti-sense transcripts in mature neutro-
phils of ANCA patients could be more significant than an
additional marker of disrupted epigenetic silencing. Anti-
sense transcripts could be templates for the production of
complementary proteins. Long non-coding RNAs identified
recently in RNA sequencing projects are thought to be ‘non-
coding’ based on computational analyses; however, these
methods ‘cannot formally reject the hypothesis that some
“non-coding” RNAs are translated in vivo or in cell lines
under biological conditions’ [13]. With this in mind, in the
case of ANCA vasculitis the presence of the anti-sense PR3
transcript would be an endogenous template for the produc-
tion of complementary PR3 protein. As documented previ-
ously, ANCA patients have antibodies that recognize
complementary PR3 protein, and it has been hypothesized
that autoantibodies against sense PR3 protein are generated
through an antibody (cPR3)-idiotypic antibody (sense-PR3)
network [14]. Evidence in favour of this hypothesis for
autoimmunity comes from studies demonstrating that
some patients with ANCA vasculitis have T cells that
respond to complementary PR3 protein [15], and the HLA
DRB1(*)1501 allele found in African Americans with PR3-
ANCA encodes a major histocompatibility complex (MHC)
class II receptor that binds sense and complementary PR3
[16]. To date, there are few additional data supporting this
hypothesis; in fact, there are some contradictory data (Peter
Heeringa, personal communication).
We have detected an anti-sense PR3 transcript in ANCA
patients (unpublished data), but whether it serves as a tem-
plate for complementary PR3 protein awaits experimental
validation. If, in fact, it is confirmed that complementary
PR3 can be produced from the anti-sense PR3 transcript,
questions still remain: is there a role for the anti-sense PR3
transcript in silencing of sense PR3? Would silencing of sense
PR3 occur post-transcriptionally via an RNAi mechanism, or
at the transcriptional level, as suggested by the model dis-
cussed above? Is the primary defect in epigenetic silencing or
is the anti-sense transcript sequestered by the translation
machinery and unavailable to initiate silencing? Is there an
anti-sense MPO transcript, and does it function similarly? By
addressing these questions, we may answer the more pro-
found question of whether the regulation of the autoantigen
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